# ABVX earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ABVX) · [Earnings tab](https://www.lopjlb.com/stock/ABVX?tab=earnings) Updated: 2026-09-23T08:07:23 Quarters analyzed: 1 ## Cross-quarter narrative The Q4 2023 earnings briefing establishes ABIVAX’s current operating runway and outlines a forward‑looking clinical agenda. Management confirmed €251 million cash on hand, sufficient to fund operations into Q4 2025, and reiterated guidance, indicating a stable financial outlook. The call introduced several new trial initiatives – Phase 2b recruitment for Crohn’s disease slated for Q3 2024 and the selection of a first follow‑on drug candidate – while confirming that the Phase 3 UC (ABTECT) readout remains on track for Q1 2025. Operational progress was highlighted with the delivery of US/European infrastructure and continued generation of pre‑clinical combination data and long‑term extension durability data. A prior enrollment delay in European C‑DIS sites was reported as resolved, yet the company flagged persistent enrollment, retention, data, pipeline, and execution risks, underscoring uncertainty around trial execution and competitive differentiation. Overall, the briefing reflects a mix of maintained guidance, new clinical milestones, and ongoing risk considerations without major shifts from prior expectations. ## Latest CallCard · Q4 ABIVAX reported €251M cash, on‑track Phase 3 UC readout Q1 2025, plans Phase 2b Crohn’s start Q3 2024, and is advancing follow‑on and combo programs while maintaining guidance. **Guidance:** maintained — Management reaffirmed sufficient cash to fund operations into Q4 2025 and kept expectations for Phase 3 readout in Q1 2025. **Tone:** mgmt 0.6 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks highlighted strong cash position, progress on Phase 3 and pipeline, indicating optimism. ### Demand visibility Clear visibility on Phase 3 readout Q1 2025 and upcoming trial initiations. Top‑line data from the Phase 3 ABTECT induction trial expected Q1 2025; Phase 2b Crohn's recruitment to start Q3 2024 with data H2 2026; preclinical combo data H2 2024; first follow‑on candidate selection Q3 2024. ### Capital allocation Raised €500M total, €251M cash to fund operations into Q4 2025. €130M crossover financing Feb, €150M debt facility Aug, €223.3M IPO Oct; cash €251M end‑2023 supports business plan through Q4 2025. ### Milestones - **Phase 3 ABTECT induction readout** [on_track]: Top‑line data expected Q1 2025. - **Phase 2b Crohn's disease recruitment** [new]: Planned start Q3 2024, data expected H2 2026. - **Preclinical combination therapy data** [on_track]: Results anticipated H2 2024. - **First follow‑on drug candidate selection** [new]: Targeted for Q3 2024. - **Operational infrastructure build in US/Europe** [delivered]: Team expanded to support global programs. - **Long‑term extension durability data** [on_track]: Cut presented at ECCO, further data expected Q3 2024. - **NASDAQ IPO** [delivered]: Raised €223.3M, largest French biotech IPO. - **Debt financing drawdown** [delivered]: Access to up to €150M. ### Fears / risks - **Enrollment risk**: Potential regional enrollment slow‑downs could affect Phase 3 timelines. - **Retention risk**: Phase 2b dropout ~12% due to headaches; retention in blinded Phase 3 uncertain. - **Data risk**: Phase 3 readout remains blinded; extent of data to be presented still under discussion. - **Pipeline risk**: Follow‑on compound criteria undisclosed, competitive landscape may limit differentiation. - **Execution risk**: Combination therapy development limited by funding for multiple human trials. - **Commercial risk**: Future payer reimbursement environment for combos uncertain. - **Competitive risk**: Large companies pursuing their own combination programs could impact market share. - **Safety risk**: Headaches observed in Phase 2b require management to avoid discontinuations. ### Key quotes > “With the cash position of €251 million as of December of '23, we have sufficient funds to finance our operations into Q4 of '25 based on current business plan.” > “We are now actually deployed in all our targeted geographic regions. We're already enrolling in China and Brazil.” ## Quarter one-liners - **2023 Q4:** ABIVAX reported €251M cash, on‑track Phase 3 UC readout Q1 2025, plans Phase 2b Crohn’s start Q3 2024, and is advancing follow‑on and combo programs while maintaining guidance. ## Theme arcs - **Guidance maintenance** (stable): Guidance unchanged, reflecting confidence in cash runway and trial timelines. - **Phase 3 UC readout** (new): Readout scheduled for Q1 2025, on‑track status noted. - **Phase 2b Crohn's recruitment** (new): Recruitment to begin Q3 2024, new trial initiation. - **Capital sufficiency** (stable): €251 M cash funds operations to Q4 2025. - **Combination therapy development** (new): Preclinical data on track, but execution risk noted. ## Fear persistence - **Enrollment risk** [new]: Potential regional enrollment slow‑downs could affect Phase 3 timelines. - **Retention risk** [new]: Phase 2b dropout ~12% and uncertain retention in blinded Phase 3. - **Data risk** [new]: Phase 3 readout remains blinded; data scope under discussion. - **Pipeline risk** [new]: Follow‑on compound criteria undisclosed; competitive differentiation uncertain. - **Execution risk** [new]: Combination therapy development limited by funding for multiple human trials. ## Guidance path 2023 Q4:maintained --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/ABVX`